About us
Founded in 1979 as an independent contract research organisation (CRO), Nuvisan initially provided bioanalytical laboratory services and PK/PD studies. Over time, it expanded into other areas such as early discovery, safety testing, clinical trial management and regulatory support. The company has grown significantly, with a focus on forming partnerships to address the changing needs of its clients. In early 2024, ALS took full ownership of Nuvisan, extending its high-quality and personalised solutions to post-commercialisation and expanding its reach to provide services in more locations worldwide.
NUVISAN HISTORY
- LAB GmbH founded as one of the first German CROs for clinical development in the pharmaceutical industry. In the early clinical phase, the company quickly develops into a full-service provider.
- Takeover by AAI International (Wilmington, NC). The company is a US-based multifunctional CRO providing GCP-, GLP- and GMP-related services to the pharmaceutical industry to support early to late product development.
- The company now trades under the name AAIPharma Deutschland. The company was renamed AAIPharma in the United States at the same time as AAI International.
- Founding as Nuvisan GmbH after the sale of the AAIPharma group to new owners.
- Expansion to Waltrop (Germany) by taking over the research institute Essex Pharma from MSD. Integration of large-scale stability programs and services. Expansion into pharmaceutical analysis of hormones, polymers and large molecules.
- Entry into non-clinical development through the acquisition and integration of the Grafing site (Germany) from long-standing partner Merck KGaA.
- Founding of Nuvisan Inc., a subsidiary of Nuvisan GmbH, in Boston, Massachusetts (USA).
- Market entry into chemistry and formulation development. Nuvisan acquires from NESTLÉ SKIN HEALTH parts of the Galderma research activities at Sophia Antipolis (France).
- Nuvisan expands its portfolio to phase 2 patient trials by acquiring the CRO INAMED in Gauting, Germany. (As of July 2024, the Gauting site is no longer part of Nuvisan.)
- Founding of Nuvisan ICB GmbH and takeover from Bayer a fully equipped pharmaceutical research unit with ~400 workplaces in the field of drug discovery.
- Nuvisan and ALS sign a strategic partnership to explore new markets. As a strategic investor, ALS (ASX: ALQ) acquires a 49% stake in Nuvisan, aiming to expand its life sciences portfolio. Since the partnership, Nuvisan has become hub for scientific excellence, innovation and technology development for the entire ALS life sciences network.
- In early 2024, ALS takes full ownership of Nuvisan by acquiring the remaining 51% shares. This strategic acquisition extends Nuvisan´s operations providing access to an extensive global network of knowledge and innovation, driving future development.
News and events
Contact us
Email us
Talk to us
Our locations
Neu-Ulm (headquarters)
Wegenerstrasse 13
89231 Neu-Ulm
Germany
Berlin
Muellerstrasse 178
13353 Berlin
Germany
Sophia Antipolis
2400 route des Colles
06410 Biot
France
Grafing
Am Feld 32
85567 Grafing
Germany
Waltrop
Im Wirrigen 25
45731 Waltrop
Germany